My points on company update:
1. to have a company update is PER SE a BIG plus (hope mr Patient is behind this new approach)
2. this update to me neutralizes aggressive expectations on Rexista; very likely we are not seeing the product in the market before 2019 (good call Wimusky). and by the way: more than 1 year since last judicial step ?? I'm not a lawyer, but does this mean Purdue is prevailing ? they have FOR SURE more than 1 year hold. anyway 9months for HAP/HAL studies on Intransal still to go. Oral abuse likely abandoned.
3. focus should be shifting on PRODRAS, which is good (I liked the "to bring this potentially differentiating technology to market” )
4. no clues on Generic Seroquel XR® and Generic Focalin XR®
5. international (to me mainly Canada, which is not small thing)
"actively pursuing opportunities it has identified outside of the U.S. to expand global market reach."
6. nothing new on possible new partnering (still pursued)"continues to pursue partnering opportunities"
7. likely actions on manufacturing and again attention to international: "focused on optimizing manufacturing and increasing marketing activities in non-U.S. markets to support product sales"
In conclusion: no mention on Cash needs and Regabatin (can be either good sign or bad sign, we just don't know).
The idea to start pushing the non-US markets (Canada, maybe UK-Australia?) is positive, mainly in the sense of being diversfied towards FDA risk...which is the elephant in the room (see ANDAs delays and Rexista-AdCOmm-Purdue lawsuit connection).
Hope mr Patient will be able to shift focus from Rexista to another big catalyzer.
News 
Market Data 
Discover 
